Table II.
Incubation time, h | Tested compound | Relative IC 50
|
||||
---|---|---|---|---|---|---|
Monotreatment | +10 nM 1α,25(OH)2D3 | +10 nM 20(OH)D3 | +10 nM 21(OH)pD | +10 nM calcipotriol | ||
24 | H2O2 | 0.017±0.07 | 0.011±0.001 | 0.013±0.0006 | 0.017±0.002 | 0.012±0.0006 |
24 | Cisplatin | 4.81±2.2 | 11.61±0.98a | 14.08±3.29b | 9.37±1.64 | 15.23±6.15b |
48 | Cisplatin | 2.57±0.19 | 1.97±0.22 | 3.47±1.04 | 3.71±1.90 | 2.13±1.01 |
48 | Dacarbazine | 1.07±0.31 | 0.45±0.35a | 1.17±0.40 | 1.04±0.36 | 0.85±0.39 |
Data are presented as the mean ± standard deviation of three independent experiments (n=6 each). The data were subjected to analysis of variance followed by Tukey’s multiple comparison test.
P<0.05 and
P<0.001 vs. monotreatment. IC50, half maximal inhibitory concentration; H2O2, hydrogen peroxide; 1α,25(OH)2D3, 1α,25-dihydroxyvitamin D3; 20(OH)D3, 20S-hydroxyvitamin D3; 21(OH)pD, 21-hydroxypregnacalciferol.